- Citing the need for caution during the COVID-19 outbreak, Provention Bio (NASDAQ:PRVB) has suspended recruitment in its Phase 3 PROTECT study evaluating teplizumab (PRV-031) in newly diagnosed type 1 diabetics.
- Currently enrolled patients will be allowed to complete treatment.
- There are no safety or efficacy issues involved.
- The company says it remains on track to file its U.S. marketing application in Q4.